|
[1] Xia L, Ni PZ, Qian JQ, et al. Preparation of phenoxyalkylamine compounds as antihypertensive agents[P]. CN Pat : 1070623.1.
[2] Fang H, Lu JF, Xia L, et al. Biophore development for prostate-selective α1-adrenoceptor antagonist[J]. Comput Appl Chem, 2000, 17, 453-456.
[3] Rathi L, Kashaw SK, Dixit A, et al. Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl )-L-tyrosines as PPAR gamma agonists [J]. Bioorg Med Chem, 2004, 12, 63-69.
[4] Arockia M, Shakya N, Prathipati P, et al. Development of 3D-QSAR models for 5-lipoxygenase antagonists: chalcones [J]. Bioorg Med Chem, 2002, 10, 4035-4041.
[5] Zhao LQ, Yuan Y, Hu YD, et al. 3D-QSAR of antiinflammatory activities of 5,6-diaryl-2,3-dihydro-1-pyrrolizinone derivatives[J]. Acta Pharm Sin, 2001, 36, 343-346.
[6] Song W, Zhang YJ, Xia L, et al. Effects of some mexiletine derivatives on alpha1-adrenoceptors [J]. Acta Pharm Sin, 1998, 33, 102-105.
[7] Xu JY, Xia L, Ni PZ, et al. Synthesis and cardiovascular activity of some benzylethylamine derivatives [J]. J China Pharm Univ, 1992, 23, 203-208.
[8] Ni PZ, Sun HB, Pen JH, et al. Resolution of α1-adrenoceptor antagonist (±) DDPH and pharmacological activity of (-) DDPH [J]. J Chin Pharm Sci, 1997, 26 (1), 51-53. |
>
>